Comparative Pharmacology
Head-to-head clinical analysis: OZURDEX versus PREDAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OZURDEX versus PREDAMIDE.
OZURDEX vs PREDAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone, a potent corticosteroid, reduces inflammation by inhibiting multiple inflammatory cytokines including prostaglandins, leukotrienes, and interleukins. It suppresses the migration of polymorphonuclear leukocytes and reverses increased capillary permeability. The mechanism involves binding to the glucocorticoid receptor, leading to regulation of gene expression that reduces production of inflammatory mediators.
Predamide (a combination of prednisolone and sulfadimethoxine) exerts its effects via the corticosteroid anti-inflammatory action of prednisolone (inhibition of phospholipase A2, reduced prostaglandin synthesis) and the bacteriostatic action of sulfadimethoxine (competitive antagonism of para-aminobenzoic acid, inhibiting dihydropteroate synthase in folate synthesis).
Single intravitreal implant of 0.7 mg (dexamethasone 700 mcg) in the affected eye; repeat dosing no sooner than 3 months after the prior implant.
Prednisone 5 mg orally once daily, adjusted based on response.
None Documented
None Documented
In the vitreous humor, the half-life is approximately 5-7 months following intravitreal implant administration. Systemic half-life is negligible due to low systemic exposure.
Terminal elimination half-life: 12-15 hours. In hepatic impairment, half-life may extend to 20-25 hours; in renal impairment (CrCl <30 mL/min), half-life increases to 30-40 hours.
Primarily hepatic metabolism via CYP3A4; metabolites excreted in feces (≈70%) and urine (≈30%). Less than 1% excreted as unchanged drug.
Renal (80% as unchanged drug and metabolites, primarily glucuronide and sulfate conjugates), biliary/fecal (20%).
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid/Sulfonamide Combination